Plus   Neg

Novartis: QMF149 Meets Primary Endpoint In Phase III PALLADIUM Trial

Novartis (NVS) announced data from the 52-week Phase III PALLADIUM trial which showed that QMF149, a fixed-dose combination of indacaterol acetate and mometasone furoate, was superior to mometasone furoate at medium and high doses in improving lung function, meeting the primary endpoint. Statistically significant superiority compared to mometasone furoate alone was demonstrated in the key secondary endpoint of improvement in asthma control.

PALLADIUM is part of PLATINUM, the Phase III clinical development program supporting the development of QVM149 and QMF149.

In the study, the overall incidence of adverse events and serious adverse events for indacaterol acetate and mometasone furoate was comparable among treatment groups.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
NBCUniversal unveiled Peacock, a free premium ad-supported streaming service with subscription tiers offering more than 600 movies and 400 series. Peacock will be available on April 15 for Comcast's Xfinity X1 and Flex customers and on July 15 for the rest of the country. NBC is offering Peacock... The number of Amazon Prime members in the U.S. is growing slowly, but steadily, a recent study has shown. According to the survey by the Consumer Intelligence Research Partners, LLC or CIRP, the number of Amazon Prime members in the U.S. is estimated to have risen to 112 million in December 2019 from just over 100 million in the same period of the prior year. Medical device manufacturer Cardinal Health will soon recall certain Level 3 surgical gowns or PreSource procedural packs that contain these gowns following warning that they may not be sterile, the U.S. Food and Drug Administration said in a statement. The health regulator said it is working with the company to find out the specific product lots that are impacted.
Follow RTT